Skip to content

Precigen PGEN Additional Paid-In Capital

Additional Paid-In Capital at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$46.37B+0.8%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$14.4B+9.2%
Gilead Sciences logo
Gilead SciencesGILD
$9.31B+14.3%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$1.95B+30.0%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$2.57B+2.6%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$1.89B+83.1%

Other financials

Income statement

See full
Revenue$23.3M+1,634%
Operating income-$6.0M+73.5%
Net income-$7.9M+85.4%
EPS (diluted)-$0.02+88.9%

Balance sheet

See full
Cash & equivalents$7.5M+23.5%
Total debt$98.3M+1,714%
Total equity$20.2M+244%
Total assets$138.6M+7.6%

Cash flow

See full
Operating cash flow-$43.8M-168%
CapEx$258.0K-58.5%
Free cash flow-$44.1M-160%

Valuation

See full
Market cap$1.91B+213%
Enterprise value$2B+234%
P/S72×

Profitability

See full
Gross margin83.6%
Operating margin-2,890.9%
Net margin-3,656%
FCF margin-1,756.5%

Returns & leverage

See full
Return on equity-843.6%-1,103pp
Debt / equity4.9×
Current ratio4.8×+1.3×

Where this comes from

Reported directly by Precigen in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: Precigen’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Precigen's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Precigen's additional paid-in capital?
Precigen (PGEN) reported additional paid-in capital of $2.37B in Q1 2026.
How has Precigen's additional paid-in capital changed year-over-year?
Precigen's additional paid-in capital increased by 11.2% year-over-year, from $2.13B to $2.37B.
What is the long-term trend for Precigen's additional paid-in capital?
Over 5 years (2020 to 2025), Precigen's additional paid-in capital has grown at a 4.6% compound annual growth rate (CAGR), from $1.89B to $2.36B.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.